V PRAT Conference 2018 in New York: From Mass Incarceration to Universal Education: Unlocking the System: October 26-27
  Everyone Is Welcome to Join In This Friday-Saturday: In New York  






Regine Humanics Foundation Ltd and The Humanion Express Solidarity and Send Best Wishes to All Attending This Oasis of Philosophy
The Arkive
|| Year Delta: London: Tuesday: October 23: 2018: We Keep On Walking On The Path of Humanics ||
Editorial Page Epigenomics Beauroblubellogenics Astrophysics Palaeontology Jurisprudence Psychology The Earth The Moon The Sunnara The Humanion Team
The Elleesium The Humanion Hearteogenics Archaeology Anthropology Geology Molecular Biology Marine World Microbial World Universana GREEN-K Hope
Elsinki The Universe Cosmology Astronomy Matter World Seismology Theatre The Arctic The Antarctic The Milky Way The Humanion Web Map

I Humanics Spring Festival 2019: April 06 in London

I Regine Humanics Annual Lecture 2019: Whither to Homo Sapiens: Delivered by Dr J Everet Green: April 06 in London


VII London Poetry Festival 2019: St Matthews at Elephant and Castle: Meadow Row: London SE1 6RG: October 14-15

Classified Adverts Holidays and Attractions Adverts Events and Festivals Adverts Employments and Opportunities Adverts Public Service Adverts Products and Services Adverts
First Published: September 24: 2015
The Humanion



The Humanion UK Online Daily


As the Mother Earth Belongs to Every Single Human Being of the Humanion Regine Humanics Foundation Ltd and The Humanion Belong to All for We are a Human Enterprise: A Not for Profit Social Enterprise: Support Your Daily Quality Newspaper and Let Us Build an Institution That Will Flow with Time with the Rainbow Peoples of This Earth Far Into the Flowing Future: Support The Humanion: Support Regine Humanics Foundation







The Eyeonium






The Eyeonium Arkive

If You Ever Doubt That The Eye is Not the Window to Your Soul Close It and You Shall Find You are Within Your Soul: The Humanion




The Science The Art The World The Universe of The Eye

New Project Gets Funding for Vital Research Into Severe Corneal Infections in Low and Middle Income Countries



|| August 11: 2018: London School of Hygiene and Tropical Medicine News || ά. The London School of Hygiene and Tropical Medicine:LSHTM has been awarded more than £03 million by the Wellcome Trust for new research into severe corneal infections in low and middle income countries:LMICs. The work will be conducted by LSHTM’s International Centre for Eye Health:ICEH, led by Professor Matthew Burton. Over a five-year period, the funding will allow an international partnership of eye health experts in Uganda, Tanzania and Nepal to carry out world-leading research to improve the outcomes for people with corneal infections.

Corneal infections are a significant public health problem in LMICs, with an estimated 04.4 million infections in Asia and 01.2 million in Africa each year. The disease, typically, affects people in adulthood during their most productive years of life and has major impacts on both quality of life and economic productivity. If, not treated rapidly or effectively, corneal infections can lead to permanent loss of vision through scarring of the cornea in the affected eye. In severe cases, the cornea, may, rupture, which, often, means that removing the eye is the only possible treatment. Infections of the cornea, the clear window at the front of the eye, are caused by either bacteria, fungi, viruses or parasites.

In developed countries, such as, the UK, most corneal infections are caused by bacteria, although, fungal infections appear to be on the rise. In certain LMICs, where the climate is hotter and more humid, fungal infections are estimated to account for over 60% of corneal infections.

Fungal corneal infections are harder to treat than bacterial infections, with existing therapies, often, being ineffective. In addition, anti-fungal eye drops are, often, unavailable in many LMICs; when they are available, they are, often, too expensive for most people to afford. Accurately recognising and differentiating the organism responsible for these infections is, also, a challenge.

To address the problems in diagnosing and treating corneal infections, the team’s research will focus on four main areas: Researching alternative, cheaper, accessible and more effective antifungal eye drops; Looking at how to reduce the damaging effects infections have on the cornea with eye drops, with a new anti-scarring treatment; Implementing early interventions in primary care to identify and treat infections quickly and Developing reliable and simple tools to aid diagnosis.

Professor Matthew Burton, of International Eye Health at LSHTM and Wellcome Trust Senior Research Fellow, said, “I am delighted that we have received this funding from the Wellcome Trust, which will allow us to carry out vital work in reducing the burden of serious corneal infections. 

These infections disproportionately affect people with the most limited resources. By focusing on both improving the diagnosis and the treatments available, we hope to improve the outcomes of those affected by corneal disease.”

Dr Simon Arunga, a PhD student at ICEH-LSHTM and an Ophthalmologist based in Uganda, said, “This funding is a great opportunity to build on our ongoing work in exploring ways to reduce the burden of avoidable blindness due to severe corneal infections.

I am excited to continue working with a group of like-minded collaborators on this project that has potential to impact the lives of many people affected by corneal infections.’’ :::ω.

|| Readmore  || 120818 || Up || 








New International Multi-Disciplinary Research Project to Understand How to Better Predict Blindness in Patients with Age Related Macular Degeneration



|| July 15: 2018: University of Southampton News || ά. A University of Southampton eye specialist is leading research using advanced imaging to predict which patients with early Age Related Macular Degeneration:AMD are at more risk of blindness. Professor Andrew Lotery, of Ophthalmology in the University’s Faculty of Medicine and Institute for Life Sciences, is leading an international research team, which has received nearly £04 million funding from the Wellcome Trust to explore what makes early AMD progress towards visual loss.

The innovative study brings together experts in ophthalmology, genetics, statistics and computer science to collaborate on the project. AMD is a very common cause of blindness with 200 million people expected to be affected by 2020, increasing to nearly 300 million by 2040. It is a complex, inherited and diverse disease, that affects the macula, the central retina, that is responsible for detailed central vision. Doctors currently don’t know who will develop the sight-threatening stage of the disease; some patients progress slowly or not at all, while others quickly deteriorate.

The five-year research project will programme computers to analyse high resolution images of the inside of the eye to identify what eye changes appear in patients with AMD and identify the structural changes, that lead to and are associated with cell degeneration in the retina in patients with early AMD.

Professor Lotery, who is, also, a Consultant Ophthalmologist at Southampton General Hospital’s eye unit, says, “Our research aims to pinpoint what makes AMD progress towards visual loss and enable us to better predict which patients will progress to the late stages of the disease. By understanding more about these markers and why AMD develops, we will be able to better inform patients, clinicians and researchers on prevention, screening, and individualised treatment strategies. 

Ultimately, it will help us make sure patients are in the right place, with some in the community and those, who need specialised treatment in hospital and will, also, help us manage capacity better.

We will be able to run clinical trials more effectively and, thus, allow faster development of new treatments. We expect the research to give us new insights into how the disease develops and new treatments will result from this.”

The project involves studying over 60,000 retinal images of patients, who have, already, had their eyes scanned as part of the UK biobank. Results from this analysis will be validated in 400 patients with early AMD, who will have their eyes scanned every four months to detect the earliest focal sites of disease progression. They will undergo advanced imaging of the major tissues; neurosensory retina, retinal pigment epithelium and choriocapillaris to identify the sequence of cell degeneration.

The study is being carried out in collaboration with established tertiary referral centres for patients with retinal disease at the University Hospital Southampton NHS Foundation Trust, Moorfields Eye Hospital:MEH, Medical University of Vienna and University Hospital Basel. It, also, involves computer science and statistic experts at Imperial College, London and genetics experts at the University of Michigan.

Principal Investigator Professor Lotery is renowned for his major contributions to preventing blindness by finding and characterising genes, that are involved in macular and photoreceptor degeneration and translating these genetic discoveries through to the clinic.

The £3,980,169 funding will allow him and his co-investigators to create the best multi-disciplinary team with a proven track record in AMD research, providing expertise in advanced image analysis, genetics, computational and trial statistics, Programmed Algorithmic Machination and comprehensive visual function evaluation.

His co-investigators are Professor Sobha Sivaprasad, University College London, Professor Toby Prevost and Professor Daniel Rueckert, Imperial College London, Professor Henrik Scholl, University of Basel, Dr Lars Fritsche, University of Michigan, Professor Ursula Schmidt-Ehrfurth and Dr Sebastian Waldstein, Medical University of Vienna. :::ω.

|| Readmore || ‽: 160718 || Up || 








New Development in Contact Lenses for Red-Green Colour Blindness Using Simple Dye



|| May 01: 2018: University of Birmingham News || ά. Researchers at the University of Birmingham have developed a contact lens, that, may, help people with colour blindness simply by using a low cost dye, according to research published on April 26 in the journal Advanced Healthcare Materials. Colour blindness or colour vision deficiency:CVD is an inherited genetic ocular disorder, in which some people have difficulty distinguishing certain colours. While no cure for this disorder exists, several methods have been used to increase the colour perception of those affected. However, current products on the market, such as, colour filtering glasses are expensive, bulky and incompatible with other vision corrective glasses.

Normal colour vision is trichromatic, which means any colour can be created by combining the colours blue, red and green, which are perceived by a cluster of cones at the back of the eye. These cones are divided into three groups, responsible for short wavelengths: blue; medium wavelengths: green and long wavelengths: red. In normal vision all three are present. When any of these cones are missing, the brain receives incorrect information leading to limited ability to identify certain colours in some people. Several companies are, already, selling glasses and custom made lenses for colour blindness correction, which can be expensive for many users, however, in this research an inexpensive soft commercial contact lens was dyed with a non-toxic rhodamine derivative dye.

This particular derivative of rhodamine was chosen as it is known for its ability to absorb certain wavelengths of light in the optical spectrum. Researchers found that the dye blocked the band, that lies between the red and green wavelengths, which is perceived by two sets of corresponding optical cones simultaneously. The removal of this band through the dyed lens inhibited the simultaneous triggering of the cones designated for green and red wavelength bands, enabling better differentiation between red and green colours.

The dyed lens was tested on people with red-green colour vision deficiency, the most common form of CVD. The dyed contact lens was applied to a glass slide. The participants were asked to look at several numbers through the dyed lens and to note whether there were any improvements to the colours or the clarity of the number. They were, also, asked to observe their surroundings and note whether they saw any improvements in their colour perception.

The results verified that dye tinted lenses can be used to enhance the colour perception of people affected by colour vision deficiency. Further patient studies are now underway.

Dr Haider Butt, Lead Researcher from the University of Birmingham’s Department of Mechanical Engineering and the Institute of Healthcare Technologies said, ''Contact lenses are of interest for colour blindness correction because it is easier to correct the entire field of view. The dye processing we carried out does not need any complex preparation, it is not toxic to the human eye and our method could be easily used in both glasses and contact lenses at low cost.

We are now looking into using a similar process to correct purple-blue colour blindness and, also, to bring together a number of dyes to make lenses perform for both red-green and purple-blue colour blindness simultaneously. We are about to commence human clinical trials shortly.’
::: ω.

|| Readmore  || ‽: 020518 || Up ||





Regine Humanics Foundation Begins Its Journey Today: The Humanion Is Now A Regine Humanics Foundation Publication


|| April 06: 2018 || ά. The Humanion was first published on September 24, 2015 and has been run, since that day, on a complete voluntary basis without any 'formal' or 'constituted' manner or form and, it was run on as a Human Enterprise, which is an idea of Humanics, in which, ownership is replaced by belongingship and, thus, in a Humanical Society, no one owns anything but everyone belongs to the whole as the whole belongs to everyone lawfully and equally and, it neither believes in nor makes money but human utilities, needs, aspirations, creativity, imagination and dreams are served without money, where everyone works and creates for all others as all others create and work for all others, thus, bringing in meaning and purpose to life along with it come natural justice, equality and liberty, that establish a true civilisation within the Rule of Law. And in one word, this system of human affairs management is called, Humanics and a society that runs itself in humanics is called a humanical society. Today, we have begun the process of 'constituting' this Human Enterprise, which does not exist in the current system, but the next closest thing to it, that exists in the UK Law is Social Enterprise. Therefore, today, Friday, April 06, 2018, we are beginning Regine Humanics Foundation, that is the 'Agency', that will lead, run, manage and develop everything, that The Humanion has been trying to do.

Regine Humanics Foundation is established by the Thinker, Author, Poet, Novelist, Playwright, Editor of The Humanion, Festival Director of London Poetry Festival and a Humanicsxian: hu: maa: neek: tian: One, that believes in, lives and exists by Humanics, Mr Munayem Mayenin, of London, England, United Kingdom. Mr Mayenin says, ''Humanics is a vision; people, may, call it, utopia, we, call it our Humanicsovicsopia; Humanics. Humanics is our philosophy, our faith, our conviction, our resolution, our way of existing, thinking, being and doing: to seek and try to do so in the determination that all we must do and be is to exist to advance the human condition. People, readers and agencies and organisations, from all across England, Scotland, Northern Ireland, Wales and the whole of the United Kingdom and Australasia, Africa, Asia, Europe, North and South America, from all walks and strata of life, have supported our endeavours, supported The Humanion and The Humanion Team, who volunteered their time to run things, since the beginning of The Humanion and long before that, when other things, that are now part of The Foundation, were developing. Nothing has changed in terms of the nature and value of what we have been seeking to do.''

''But the founding of The Foundation brings it all in a solid foundation so that we can keep on building this 'vision' so that it keeps on going regardless of who come to take the vision-mission of The Foundation forward. The Foundation runs along with time and along with the flowing humanity. This is the dream, this is the vision, this the hope in founding this Foundation. And, in this, we hope and invite all our readers, supporters, well wishers and all agencies and organisations to support our endeavours to build something, a Human Enterprise, which we are in the process of registering as a Social Enterprise, as a Community Interest Company, working for the common good of the one and common humanity. No one makes or takes profit out of The Foundation, which now runs The Humanion and everything else, that is part of it. The Foundation, once registered, will have an Asset Lock, which means that in any event, should The Foundation dissolve itself, all its existing assets shall go to a similar Social Enterprise. Therefore, we invite everyone to support The Foundation, support The Humanion in whatever way they can. And, there are endless number of ways people and organisations can support The Foundation and The Humanion.'' ::: ω.

||  Readmore  || ‽: 060418 || Up   || 





Micro-Environment of Diabetic Retinopathy Supports Lymphatic Neo-Vascularisation







|| March 30: 2018: University of Helsinki News: Päivi Lehtinen Writing  || ά. “We asked whether Proliferative Diabetic Retinopathy involves the growth of new lymphatic vessels in addition to blood vessels and, indeed, we found, expression of lymphatic markers in the PDR tissues.” This new study, conducted at the University of Helsinki, was published in the Journal of Pathology. Proliferative Diabetic Retinopathy is a major sight-threatening diabetic complication. Nearly, all patients with type one iabetes and over 60% of patients with type two I diabetes develop retinopathy after 20 years of diabetes, despite metabolic control.

PDR comes into existence through the process of pathological angiogenesis, when endothelial cells of the retinal vasculature invade their surroundings and project into the vitreous, the gel substance present inside the eye. The new vessels are fragile and leaky, which leads to vitreous haemorrhage and a fibrotic response, that will, eventually, pull the retina causing retinal detachment and, subsequent, vision loss. When these vessels develop, diabetic patients are directed to vitreo-retinal surgery, whereby the newly formed pathological fibro-vascular tissue is excised.

''Given the fact that current diabetic mouse models do not, fully, recapitulate this human diabetic eye complication, our research group set out to utilise these excised neo-fibro-vascular tissues for the in-depth characterisation of the disease pathophysiolog.'' says Researcher Ms Erika Gucciardo at the University of Helsinki.

One major question the group had was to understand the nature of these vessels. ''Chronic tissue inflammation is present in Proliferative Diabetic Retinopathy and we know it is connected with lymphangiogenesis. Therefore, we asked whether Proliferative Diabetic Retinopathy involves the growth or differentiation of new lymphatic vessels.'' says Mr Gucciardo.

The researchers found, indeed, expression of lymphatic markers in the PDR tissues. ''It is, increasingly, clear that studying the micro-environment is of fundamental importance to understand the mechanisms of a disease. The close collaboration between clinics and research laboratory opened such avenue.'' says Research Director Ms Kaisa Lehti, Karolinska Institutet and University of Helsinki.

Vitreous samples were collected peri-operatively and used to understand the contribution of the diabetic intra-ocular micro-environment to the lymphatic endothelial involvement. The researchers found that, indeed, vitreous samples with increasing concentration of major lymphangiogenic growth factor VEGFC supported the lymphatic endothelial identity and corresponded to fibro-vascular tissues with lymphatic marker expression.

The functionality of these vessels in PDR pathogenesis remains to be investigated.  ''It will be interesting to know whether these lymphatic vessels develop coincidentally with abnormal blood vessels or only later upon PDR progression and whether they are detrimental or beneficial, e.g, towards fluid removal and inflammatory cells trafficking.'' Mr Gucciardo says.

All together these discoveries bring a new concept to diabetic micro-vascular complications and can lead to new treatment approaches.

''In the future, therapeutic strategies targeting both lymphangiogenesis and angiogenesis, may, represent promising approaches for treating ischemia and inflammation-associated posterior segment retinal diseases, states ophthalmic surgeon.'' Dr. Sirpa Loukovaara from Helsinki University Hospital.

The Paper: Microenvironment of proliferative diabetic retinopathy supports lymphatic neovascularization: Erika Gucciardo, Sirpa Loukovaara, Ani Korhonen, auliina Repo, Beatriz Martins, Helena Vihinen, Eija Jokitalo and Kaisa Lehti: Journal of Pathology 2018 ::: ω.

||  Readmore  ||  || ‽: 310318 ||  Up  ||







Breakthrough in the Treatment of Age Related Macular Degeneration



|| March 20: 2018: Moorfields Eye Hospital News || ά. Patients regain sight after being the first to receive retinal tissue engineered from stem cells. Successful trial on patients using new stem cell based treatment for wet age related macular degeneration:AMD. The results from a clinical study suggest the treatment is safe and effective. The study is a major milestone for the London Project to Cure Blindness and could lead to an ‘off-the-shelf’ treatment within five years. The results of this ground-breaking clinical study, published in Nature Biotech, described the implantation of a specially engineered patch of retinal pigment epithelium cells derived from stem cells to treat people with sudden severe sight loss from wet AMD. It is hoped that it will, also, help treat dry AMD in the future.

It’s the first description of a complete engineered tissue, that has been, successfully, used in this way. The study is a major milestone for the London Project to Cure Blindness, a partnership between Moorfields Eye Hospital NHS Foundation Trust, the UCL Institute of Ophthalmology and the National Institute for Health Research:NIHR. AMD is the most common cause of sight loss in the UK and can lead to a rapid loss of central or reading vision. The two patients, who underwent the procedure, a woman in her early 60s and a man in his 80s, had the severe form of the condition, wet AMD and declining vision. The study investigated whether the diseased cells at the back of the patients’ affected eye could be replenished using the stem cell based patch. A specially engineered surgical tool was used to insert the patch under the retina in the affected eye of each patient in an operation lasting one to two hours.

The patients were monitored for 12 months and reported improvements to their vision. They went from not being able to read at all, even, with glasses, to reading 60-80 words per minute with normal reading glasses. Mr Douglas Waters, 86, from Croydon, London, was one of the two people, who had received the treatment at Moorfields Eye Hospital. He developed severe wet AMD in July 2015 and received the treatment three months later in his right eye.

He says, “In the months before the operation my sight was really poor and I couldn’t see anything out of my right eye. I was struggling to see things clearly, even, when up-close. After the surgery my eyesight improved to the point, where I can now read the newspaper and help my wife out with the gardening. It’s brilliant what the team has done and I feel so lucky to have been given my sight back.”

Professor Lyndon da Cruz, Consultant Retinal Surgeon at Moorfields Eye Hospital NHS Foundation Trust, said, “The results suggest that this new therapeutic approach is safe and provides good visual outcomes. The patients, who received the treatment had very severe AMD and their improved vision will go some way towards enhancing their quality of life. We recognise that this is a small group of patients but we hope that what we have learned from this study will benefit many more in the future.”

Professor Pete Coffey, UCL Institute of Ophthalmology, said, “This study represents real progress in regenerative medicine and opens the door to new treatment options for people with age-related macular degeneration. We hope this will lead to an affordable ‘off-the-shelf’ therapy that could be made available to NHS patients within the next five years.”

The London Project to Cure Blindness

'Phase One clinical study of an embryonic stem cell–derived retinal pigment epithelium patch in age-related macular degeneration is published in Nature Biotech: DOI 10.1038/nbt.4114

How the procedure works: The retina is made of many different layers. One of the critical layers, called, the retinal pigment epithelium:RPE separates blood vessels from the nerve layer and nourishes the retina. This layer is damaged in patients with AMD. In this new approach, researchers took a stem cell, which is a single cell and reproduced it many times, turning them into a perfect copy of the RPE layer, that needs to be replaced in patients with AMD. This is, then, placed onto a patch and inserted under the retina to replace the damaged cells.

Age-related macular degeneration:AMD is the most common cause of sight loss in the developed world. More than 600,000 people are affected by AMD in the UK:Macular Society. It, usually, affects people over the age of 60. There are two types of AMD, wet and dry. Wet AMD develops, when abnormal blood vessels grow into the macula. These leak blood or fluid, which leads to vision loss and secondary scarring of the macula and, in some cases, rapid loss of central or reading vision. There is no cure for wet AMD but it can be treated by injecting drugs into the eye to stop the growth of the abnormal blood vessels. These injections are needed regularly to preserve vision.

Dry AMD is the most common type of macular degeneration and affects 90% of the people, who have the condition. In the dry form, there is a breakdown or thinning of the layer of retinal pigment epithelial cells:RPE in the macula. These RPE cells support the light sensitive photoreceptor cells, that are so critical to vision. There is no treatment at present for dry AMD after the photoreceptors are lost.

The London Project to Cure Blindness is collaboration between Professor Pete Coffey from University College London and Professor Lyndon da Cruz, a Retinal Surgeon at Moorfields Eye Hospital. The project aims to bring stem cell therapy for retinal diseases, especially, for age-related macular degeneration:AMD to the clinic as rapidly as possible. We believe stem cell based therapies for these conditions have the greatest chances of preventing blindness, restoring sight and improving sufferers’ quality of life in the future.

The London Project to Cure Blindness was established by a philanthropic donation from an anonymous American donor. Philanthropy plays a significant role in funding the programme, including, continued support from Moorfields Eye Charity.

The London Project to Cure Blindness receives support from an anonymous philanthropic American donor, The Lincy Foundation USA, Moorfields Eye Charity, NIHR Biomedical Research Centre at Moorfields and the UCL Institute of Ophthalmology, the Macular Society, the UK Medical Research Council:MRC, Cells for Sight manufacturing facility at the UCL Institute of Ophthalmology and Moorfields, Pfizer Inc, CIRM Bowes Foundation.

Moorfields Eye Hospital NHS Foundation Trust is a world-leading provider of eye care services in the UK. We provide a wide range of clinical services, caring for patients in over 30 locations in and around London to provide expert treatment closer to patients’ homes. We, also, operate commercial divisions, that provide care to private patients in both London and the Middle East. With our academic partner, the UCL Institute of Ophthalmology, we are recognised as a leading centre of excellence in eye research and education.

UCL Institute of Ophthalmology is one of a number of specialised biomedical research centres within UCL. We conduct advanced science, attracting research workers of the highest international calibre. In recognition of the Institute’s international standing, the most recent Higher Education Funding Council for England:HEFCE Research Evaluation Framework exercise confirmed the outstanding quality of research carried out at the Institute. According to the 2017 Centre for World University Rankings, UCL is the best place in the world to study ophthalmology.

The National Institute for Health Research:NIHR
 Moorfields Biomedical Research Centre:BRC was established in April 2007 and awarded its third five-year term by the NIHR in April 2017. Alongside the NIHR Moorfields Clinical Research Facility:CRF for Experimental Medicine, our main purpose is to accelerate the progress of biomedical research from the laboratory into early phase safety trials so that scientific breakthroughs, that hold promise for patients can proceed along the clinical testing pathway more quickly. Our BRC is one of 20 Biomedical Research Centres awarded to NHS:university partnerships with an outstanding international reputation for research. As a partnership between Moorfields Eye Hospital and UCL Institute of Ophthalmology we are at the centre of one of the largest ophthalmic research sites in the world.

Moorfields Eye Charity supports the work of Moorfields Eye Hospital and its research partner, the UCL Institute of Ophthalmology, making a difference for patients at the hospital and for people with sight problems around the world. It provides grants and raises money to help the hospital provide the best possible care for its patients, educate the researchers and clinicians of tomorrow and support leading-edge research that aims to develop new treatments for blinding diseases. ω.  

||  Readmore  ||  ‽: 200318  || Up   ||








Photonics: Our Specialty Optical Fibre Inventions Now Navigate Airliners Cut Steel and Can Be Found on the Moon Mars and the International Space Station...And Perhaps One Day Even Propelling Spacecraft Through the Universe


|| February 26: 2018: University of Southampton News  || ά. A delegation from the University of Southampton has visited the Buckingham Palace for ceremonies to receive the prestigious Queen’s Anniversary Prize for Higher and Further Education. The Prize, awarded for the University’s world-leading expertise in photonics and fibre optic technology, was presented by HRH Prince Charles and Southampton Honorary Graduate HRH the Duchess of Cornwall to Professor Sir David Payne and Professor Nikolai Zheludev from Southampton’s world-renowned Optoelectronics Research Centre. The Queen's Anniversary Prizes are the UK's most prestigious form of recognition for a UK academic or vocational institution, with approval directly from The Queen and Parliament.

Also, representing the University at the Palace were Philip Greenish, Vice Chair of Council, Research Fellow Dr Katrina Morgan, PhD researchers Ms Andrea Ravagli, Mr Alex Jantzen, Ms Angeles Camachoand and Mr Ausra Cerkauskaite. Sir David Payne, Director of the ORC, said, “Being honoured with this prestigious award is recognition of just how important Photonics is to the UK and the extensive role the University of Southampton has played in leading Photonics research since the 1960s.” Professor Sir Christopher Snowden, President and Vice-Chancellor of the University, said, “I am delighted that the University of Southampton has been awarded a Queen’s Anniversary Prize for its highly-regarded work in photonics.

This is a really exciting opportunity for the University to celebrate an important award and recognise the contributions made by our Opto-electronics Research Centre over many years.” Inspired innovations by the ORC over many decades has led to the development of a vibrant community of over 200 staff and postgraduate students working on advanced research in Photonics, the science and technology of light, to provide solutions for real-life problems.

Formally established in 1989, the ORC is now the largest and longest established centre of its kind in the UK, leading breakthroughs in optical fibres, laser manufacturing, next generation computing and new optical materials, that power the internet, feed mobile telephone networks and help make life-saving devices, that transform our daily lives.

As well as, its extensive links with companies and universities around the world, the ORC leads a new national manufacturing hub for the UK. It has, also, been responsible for developing a major research and commercial nucleus within Southampton and the surrounding area with at least 10 companies ‘spinning out’ to provide employment and inward investment to the region from its work.

Outreach activities have, also, been a hallmark of the ORC with schools and colleges benefitting from activities designed to encourage more students to study physics and support the teaching of photonics in schools whilst engaging them in research and the wider promotion of careers within physics and engineering. Activities, including, the Photonics Explorer workshop and The Light Express Roadshow reach thousands of school-age pupils and students each year.

“Over fifty years ago the ORC received global recognition for developing one of the world’s first ultra-low loss optical fibres.” said Sir Payne. “From there we were the first to announce another vital component, that allows the internet to span the world, the optical fibre amplifier, that, periodically, boosts the signals. Today hundreds of millions of kilometres of optical fibre carry the signals on the internet.

Our specialty optical fibre inventions now navigate airliners, cut steel and can be found on the moon, Mars and the International Space Station.” he continued. “These special fibres are capable not just of carrying internet data but have many different applications, such as, in gyroscopes, high-powered lasers and, perhaps, one day, even, propelling spacecraft through the universe.

The next big challenge in Photonics is how we make everything smaller, more complex, more functional and cheaper. This requires the development of new materials, which don’t exist in the natural world, such as, metamaterials and silicon itself for the development of tiny silicon optical chips. There is in prospect a new generation of hollow fibres, which can carry, even, more data, at far greater speeds, so the world can realise the capabilities of five-G and beyond.” he concluded.

This award marks the third time the University of Southampton has received recognition via the Queen’s Anniversary Prizes. In 2011, Southampton was honoured for its Performance Sports Engineering Laboratory supporting high-performance sports competitors, including several Olympic Gold Medal winners, such as, track cyclist Sir Chris Hoy and skeleton athlete Ms Amy Williams. In 2005, Southampton’s Institute for Sound and Vibration Research received the award for its many contributions to business and the wider community including efforts to make aircraft quieter, improving the efficiency of cochlear implants for people with hearing loss, improving sound systems and understanding the mechanisms of bubble acoustics.

Caption 01: ORC Research Fellow Dr Katrine Morgan with PhD researchers Andrea Ravagli, Alex Jantzen, Angeles Camacho and Ausra Cerkauskaite: 02: Professor Nikolai Zheludev with Southampton Honorary Graduate, HRH The Duchess of Cornwall: 03: 02: ORC Director, Professor Sir David Payne, receives the Queen's Anniversary Prize from HRH Prince Charles: Images: University of Southampton ::: ω.

||  Readmore   ||  ‽: 260218  ||    Up   ||






Statins Found to Help Prevent Scar Tissue in the Eye


|| January 29: 2018: University of Helsinki News: Päivi Lehtinen Writing || ά. According to a Finnish study, Statin medication seems to reduce the risk of repeated surgery in patients, who undergo a vitrectomy to treat a detached retina. The researchers believe that Statins, might, prevent the formation of scar tissue inside the eye. Conducted at the Helsinki University Hospital, the population-based cohort study is based on an extensive store of register data of Finnish patients, who have undergone vitreo-retinal eye surgery. The study examined renewed surgeries among 5,709 eye patients, who were admitted to hospital for a vitreo-retinal surgical procedure between 2008 and 2014.

The results indicate that use of Statin medication at the time of surgery was associated with a 28% reduction in the risk of renewed surgery among patients, who underwent a primary vitrectomy to treat retinal detachment. However, Statin medication was not found to be associated with a reduced risk of renewed surgery in the other vitreo-retinal disease groups involving retinal surgery, such as, age-related macular pucker formation or vitrectomies performed to treat diabetic retinopathy. “It seems that Statin treatment is beneficial in the treatment of retinal detachment, the most serious common retinal disorder, which, may, at worst, lead to blindness.” says Docent Ms Sirpa Loukovaara from the HUCH eye clinic, who led the study.

“This means that systemic Statin medication, may be, beneficial not only in the prevention of cardio-vascular diseases but, also, in terms of eye health.” The researchers believe that the benefits of Statin medication on retinal detachment patients is, probably, due to the effect of the Statin medication on reducing the inflammation inside the eye and hindering the formation of scar tissue.

“Our previous work has indicated that the amount of biochemical markers related to the scar tissue formation is lower in the vitreous gel of subjects receiving Statin medication than it is in the vitreous gel of control subjects without Statin and, therefore, we considered it necessary to investigate further our findings.” states Ms Loukovaara.

While the results are significant for ophthalmology, they will not directly change the treatment practices of patients, who have undergone surgery for retinal detachment. They do, however, invite further study.

“At the moment there is no safe drug treatment, that could prevent the formation of scar tissue inside the eye, so we should study the potential benefits of Statins in this area. It’s possible that in the future, retinal detachment patients thought to benefit from the treatment would receive Statin medication as an implant or as an injection inside the eye.” says Ms Loukovaara.

Further information: Docent Sirpa Loukovaara, HUCH and the University of Helsinki: email: sirpa.loukovaara at hus.fi :::

|| Readmore  ||  ‽: 290118  ||    Up   ||





600,000 People in the UK are Affected  by Macular Degeneration


|| January 24: 2018 || ά. The National Institute for Health and Care Excellence:NICE, has issued new guideline making recommendations about diagnosing, monitoring and treatment, as well as, the information and support, that should be offered to patients of Age-related Macular Degeneration:AMD, which is the term given to ageing changes, that occur in the central area of the retina or the macula, that affect a person’s ability to perform daily activities, such as driving, reading and recognising faces.

According to the Macular Society, over 600,000 people in the UK are affected by AMD, which is increasing as the population ages. AMD is classified as early, intermediate or late according to the stage of disease progression. It is then further classified into two forms; dry and wet. Dry AMD progresses slowly and requires monitoring, whereas, the wet form can lead to a rapid worsening of vision. The guideline recommends that people with suspected late AMD, wet active, are referred to a macula service quickly so that they can be given a prompt diagnosis and fast access to effective treatments.

For eyes with confirmed late AMD, wet active, anti-vascular endothelial growth factor or anti-VEGF drugs should be offered within 14 days of referral to the macula service. Anti-VEGF treatment is recommended in accordance with existing NICE technology appraisal guidance for treating late AMD or wet active. These drugs are injected into the eye and prevent the abnormal growth of blood vessels, which cause the deterioration in sight.

Professor Mark Baker, Director of the Centre for Guidelines at NICE, said, “AMD can be a life changing condition for people if it is not identified early on. There are around 26,000 new cases of wet AMD in the UK each year and if left untreated over half will become visually impaired or blind within three years. Therefore, the need to provide timely diagnosis and treatment is important.”

In all cases the recommendations are for people with visual acuity between 06:12 and 06:96. In eyes with visual acuity worse than this, the guidance recommends that treatment should be considered if it’s expected to improve the person's overall visual function, for example, if the affected eye is the person’s better-seeing eye.

It, also, states that anti-VEGF treatment in eyes with a visual acuity better than 06:12 is clinically effective and, may be, cost effective depending on the regimen used. The guideline includes recommendations on non-drug strategies to manage AMD, such as, group based rehabilitation programmes.

Dr Waqaar Shah, GP at Chatfield Health Care and Chair of the Guideline Committee, said, “People with AMD can feel isolated and are at increased risk of depression. It is important they are given the right support at the right time to help them with this condition. This new guideline will help ensure therapeutic, social and psychological support is available to help patients in their daily lives.”

NHS organisations should compare their current practice with these recommendations and consider what changes, may, need to be made to put them into practice. In considering any changes, they will need to take into account any extra costs and savings involved. The speed at which these recommendations are adopted by local NHS services will depend on the resources they have available and the other priorities they are dealing with. :::

||  Readmore  || ‽: 240118  ||    Up   ||


For Stories Published in The Eyeonium in Year Gamma Arkive

The Eyeonium











Inside Image: University of St Andrews

The Eyeonium

And The Eye once opened and saw there was the light
That formed a print as if a light-tree had sprung over it
And The Eye wore that light-tree as a a sudden moon
That it had not yet seen but wore it ee shone it singing

Then The Eye saw that it could see other eyes looking at
It all tear-written and joy-strung and awe-sung they all
Looked and The Eye said such a beautiful thing to see in
The Light the Joy the Sorrow the Pearl in tears sparkling

And The Eye saw and loved the light ee the luminous that
It makes true and The Eye heard the silence as a tongue
Ee sung it as the earth has forever done to the silent moon

Being loving singing shining seeing ee reaching The Eye
Sees and loves and sings and keeps shining in light yet
In the dark The Eye an Aria-Universe a-bloom a silence

Munayem Mayenin: January 24: 2017


The Eye is the window to a human soul: this common wisdom of humanity, is such that, it is very possible, if one goes searching, one could find this wisdom, in all the human languages and cultures. One cannot hide what and who one is from one's eye. And no one ever forgets an eye, once one has seen it. A human being primarily thinks, remembers, of someone by registering their eye. And a human can go on communicating with fellow humans with her:his eyes without using a spoken language. And the Eye shows us that there exists the human soul that communicates in more than one mediums and that the 'spoken' human language is not 'the medium' for it to use to communicate, to express, to create, to be and to connect.

In this, human eyes have their own 'language' that can express one's inner most state without ever having to resort to using a spoken language. Why is human eye such a magnificent thing? As science goes, it is a magnificent thing. The eye is the closest neighbour of the brain and the best connected friend of the heart for if the heart is in wuthering a state, the eye cannot hide it nor can it stay remote and not feel it nor can it not break into tears or into sunshine smiles when that is the state in the Sanctum Mayakardium. The Eye, the wonder, the window, the one time, the one space and the all time-space exuberant expression of the human existence and this very eye, physically lets us validate, confirm our own existence, as do other senses but the Eye reigns supreme. And, the Eye, when all physicality has ceased, and one is one with one's own being, own existence, one still finds, the Eye is not just a physical thing for it exists non-physically, too, as the mind does so that we have the expression, the Mind's Eye. So the Eye and the Mind or Soul are inseparable. They are the one and the same. And probably, from this, has arisen, the eye, being the window to the soul.

Here, is The Eyeonium for this Eye: the science, the art, the world, the universe of The Eye. That includes everyone that can and do have something to say about the Eye. So, please, say it: send your say, science, art, world, universe of the eye from hospital Ophthalmology departments, universities, opticians and eye clinics and optics and physics as well as art of all forms and mediums or in short, anything and everything to do with The Eye. Except, please, remember, The Humanion does do product promotions. The Humanion opens The Eye and gives you The Eyeonium. The Humanion Team: January 24: 2017

This is The Eye: By Charlotte Epstein 










Life's Laurel Is You In One-Line-Poetry A Heaven-Bound Propagated Ray Of Light Off The Eye Of The Book Of Life: Love For You Are Only Once



Life: You Are The Law The Flow The Glow: In Joys In Hurts You Are The Vine-Songs On The Light-Trellis


























|| All copyrights @ The Humanion: London: England: United Kingdom || Contact: The Humanion: editor at thehumanion.com || Regine Humanics Foundation Ltd: reginehumanics at reginehumanicsfoundation.com || Editor: Munayem Mayenin || First Published: September 24: 2015 ||
|| Regine Humanics Foundation Ltd: A Human Enterprise: Registered as a Not For Profit Social Enterprise in England and Wales: Company No: 11346648 ||